BNP Paribas Financial Markets’s Clovis Oncology, Inc. CLVS Stock Holding History

BNP Paribas Financial Markets’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,117	Closed	-$1.33K	–	4929
2022 Q3	$1.33K	Sell	1,117 -45,443	-98%	-$70.8K	﹤0.01%	4396
2022 Q2	$83.8K	Buy	46,560 +38,578	+483%	+$56.9K	﹤0.01%	3409
2022 Q1	$16.1K	Sell	7,982 -14,014	-64%	-$27.5K	﹤0.01%	3750
2021 Q4	$59.6K	Buy	21,996 +2,287	+12%	+$8.45K	﹤0.01%	3706
2021 Q3	$87.9K	Buy	19,709 +16,123	+450%	+$77.7K	﹤0.01%	3325
2021 Q2	$20.8K	Sell	3,586 -6,539	-65%	-$38.3K	﹤0.01%	3522
2021 Q1	$71.1K	Sell	10,125 -32,015	-76%	-$215K	﹤0.01%	3498
2020 Q4	$202K	Buy	42,140 +12,128	+40%	+$61.3K	﹤0.01%	2877
2020 Q3	$175K	Sell	30,012 -251,970	-89%	-$1.51M	﹤0.01%	2820
2020 Q2	$1.9M	Sell	281,982 -9,011	-3%	-$68.2K	﹤0.01%	1519
2020 Q1	$1.85M	Buy	290,993 +216,013	+288%	+$1.73M	﹤0.01%	1527
2019 Q4	$782K	Buy	74,980 +4,019	+6%	+$29.2K	﹤0.01%	2180
2019 Q3	$279K	Buy	70,961 +33,981	+92%	+$275K	﹤0.01%	2559
2019 Q2	$550K	Sell	36,980 -10,453	-22%	-$189K	﹤0.01%	1956
2019 Q1	$1.18M	Buy	47,433 +31,435	+196%	+$788K	﹤0.01%	1631
2018 Q4	$287K	Sell	15,998 -963	-6%	-$19.7K	﹤0.01%	1985
2018 Q3	$498K	Buy	16,961 +4,664	+38%	+$181K	﹤0.01%	2029
2018 Q2	$559K	Buy	12,297 +2,472	+25%	+$120K	﹤0.01%	1963
2018 Q1	$519K	Buy	9,825 +732	+8%	+$42.7K	﹤0.01%	2186
2017 Q4	$618K	Buy	9,093 +3,895	+75%	+$272K	﹤0.01%	2336
2017 Q3	$428K	Sell	5,198 -52	-1%	-$4.12K	﹤0.01%	2068
2017 Q2	$492K	Buy	5,250 +4,446	+553%	+$272K	﹤0.01%	1918
2017 Q1	$51.2K	Sell	804 -1,472	-65%	-$89.5K	﹤0.01%	2730
2016 Q4	$101K	Sell	2,276 -363	-14%	-$12.8K	﹤0.01%	2519
2016 Q3	$95.1K	Buy	2,639 +1,405	+114%	+$30.1K	﹤0.01%	2127
2016 Q2	$16.9K	Buy	+1,234	New	+$18K	﹤0.01%	2653
2016 Q1	–	Sell	-6,726	Closed	-$235K	–	3195
2015 Q4	$235K	Buy	6,726 +1,154	+21%	+$74.4K	﹤0.01%	1830
2015 Q3	$512K	Buy	5,572 +3,503	+169%	+$303K	﹤0.01%	1351
2015 Q2	$182K	Buy	2,069 +1,483	+253%	+$127K	﹤0.01%	1753
2015 Q1	$43.5K	Buy	+586	New	+$41.4K	﹤0.01%	1986
2014 Q4	–	Sell	-1,455	Closed	-$66K	–	3417
2014 Q3	$66K	Buy	+1,455	New	+$60.8K	﹤0.01%	2444
2014 Q1	–	Sell	-229	Closed	-$13.8K	–	3907
2013 Q4	$13.8K	Sell	229 -3,865	-94%	-$210K	﹤0.01%	2440
2013 Q3	$249K	Sell	4,094 -842	-17%	-$59.7K	﹤0.01%	2069
2013 Q2	$331K	Buy	+4,936	New	+$222K	﹤0.01%	1913

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BNP Paribas Financial Markets's CLVS Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 1,117 shares — an estimated $1.33K sold.

BNP Paribas Financial Markets first reported a position in CLVS in Q2 2013 and held it in 34 quarters. The position peaked at $1.9M in Q2 2020. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

BNP Paribas Financial Markets reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
BNP Paribas Financial Markets sold 1,117 Clovis Oncology, Inc. shares in Q4 2022, an estimated $1.33K.
BNP Paribas Financial Markets first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 34 quarters.
BNP Paribas Financial Markets's Clovis Oncology, Inc. position peaked at $1.9M in Q2 2020.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.